• Bilgul Mete, Alper Gunduz, Hayat Kumbasar Karaosmanoglu, Fatma Gumuser, Sibel Bolukcu, Dilek Sevgi Yildiz, Ozlem Altuntas Aydin, Bilgenur Bilge, Ilyas Dokmetas, and Fehmi Tabak.
• Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine Department of Infectious Diseases and Clinical Microbiology.
• Afr Health Sci. 2021 Dec 1; 21 (4): 1593-1602.

BackgroundEfficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (E/C/F/TDF) in treatment-naïve and experienced patients with HIV infection was demonstrated in phase 3 trials. The primary objective of this study was to evaluate effectiveness and safety of E/C/F/TDF in real world settings.MethodsRetrospective, observational data collected by the Turkish ACTHIV-IST study group between May 2015 and December 2016 were analysed.ResultsA total of 387 patients were prescribed E/C/F/TDF; 210 patients with available data at 6th month were eligible; 91.5% were male, and mean age was 35.2 (SD: 10.8) years; 54.0% of males identified themselves as MSM. Sixty-three percent (133) of the study population were treatment-naïve patients, and 37% (77) were treatment experienced. HIV RNA level was below 100 copies/mL in 78.9% of treatment-naïve patients and 89.9% of treatment experienced patients at month 6. Median increase in CD4 T lymphocyte count was 218 copies/mL in treatment-naïve patients and remained stable or increased in treatment experienced patients. Adverse events were observed in 15% of the patients, and the regimen was discontinued in only six patients.ConclusionReal world data on the effectiveness and safety of E/C/F/TDF is comparable with the phase 3 trial results Adverse events are uncommon and manageable.© 2021 Mete B et al.

23 keywords...

hide…